Insulet Taps Stryker Veteran Panos as Chief Commercial Officer to Drive Global Expansion
Event summary
- Mike Panos joins Insulet as EVP and Chief Commercial Officer effective immediately.
- Panos brings 30 years of medical technology commercial leadership, most recently at Stryker.
- He will lead global commercial strategy, market expansion, and operational performance.
- Insulet aims to accelerate growth through automated insulin delivery technology adoption.
The big picture
Insulet's appointment of Mike Panos underscores its push to strengthen commercial capabilities amid growing adoption of automated insulin delivery. The move comes as the company seeks to expand its market reach beyond type 1 diabetes into type 2 and other therapeutic areas, leveraging its tubeless insulin pump technology. Panos's experience in scaling sales organizations and driving market expansion at Stryker positions him to navigate the competitive landscape and support Insulet's global ambitions.
What we're watching
- Execution Risk
- How Panos's track record at Stryker translates to Insulet's commercial strategy.
- Market Expansion
- The pace at which Insulet can penetrate new patient populations and care settings.
- Global Growth
- Whether Insulet can sustain double-digit growth in competitive diabetes management markets.